Beta Drugs Limited has informed about their 2024-25 investor presentation, highlighting strong growth in domestic brands and international business, surpassing 100 Cr in domestic oncology sales, with a robust EBITA margin of 22.4%. They emphasize R&D, compliance, and expanding market presence in 46+ countries.